BNC KOREA, Inc.
Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.
As of 2026-10-11, BNC KOREA, Inc. has 43 Korean MFDS device approvals, 8 Korean MFDS drug approvals, 1 PubMed-indexed paper on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Products & technology
- HA FillerHyaluronic acid-based dermal filler for volume and wrinkle improvement
- Botulinum toxin pharmaceuticalWrinkle improvement, muscle spasm, and hyperhidrosis treatment
- Collagen-based absorbable wound dressingWound dressing
- Anti-adhesion materialPost-surgical adhesion prevention
- I.stDerma-cosmetic brand (skin regeneration, whitening, wrinkle care)
Regulatory approvals
data.go.kr8 Korean MFDS drug approvals · 2012–2024 / 43 Korean MFDS device approvals · 2008–2022
- MFDS drugBIENOX Injection 200 unit(Clostridium Botulinum Toxin Type A)(for export)2024-11-28Drug · Prescription · Approval202402821
- MFDS drugBIENOX Injection(Clostridium Botulinum Toxin Type A)2024-03-21Drug · Prescription · Approval202400591
- MFDS drugMabenfomin Soft Capsule2023-02-28Drug · OTC · Notification202300719
- MFDS drugBNCDapa Tab.2023-01-31Drug · Prescription · Approval202300425
- MFDS drugTopcondor 600 Tab.Revoked2022-09-16Drug · OTC · Notification202203582
- MFDSGraft/prosthesis, biomaterial2022-06-02Product approval · Class 4제허 22-364 호
- MFDSGraft/prosthesis, biomaterial2022-01-28Product approval · Class 4제허 22-71 호
- MFDSGraft/prosthesis, biomaterial2021-09-29Product approval · Class 4제허 21-806 호
- MFDSGraft/prosthesis, biomaterial2021-08-06Product approval · Class 4제허 21-670 호
- MFDSDressing, fluid-impermeable film2021-01-27Product approval · Class 2제인 21-4056 호
- MFDSGraft/prosthesis, biomaterial2021-01-20Product approval · Class 4제허 21-48 호
- MFDSGraft/prosthesis, biomaterial2020-12-18Product approval · Class 4제허 20-1106 호
Show 39 more
- MFDSTissue supplement, collagen2020-09-01Product approval · Class 4제허 20-768 호
- MFDS drugBIENOX Injection(Clostridium Botulinum Toxin Type A)(for export only)2020-01-13Drug · Prescription · Approval202000204
- MFDSGraft/prosthesis, biomaterial2019-09-06Product approval · Class 4제허 19-579 호
- MFDSTissue supplement, collagen2019-07-18Product approval · Class 4제허 19-470 호
- MFDSGraft/prosthesis, biomaterial2019-04-17Product approval · Class 4제허 19-255 호
- MFDSGraft/prosthesis, biomaterial2019-04-17Product approval · Class 4제허 19-254 호
- MFDSGraft/prosthesis, biomaterial2018-10-10Product approval · Class 4제허 18-667 호
- MFDSGraft/prosthesis, biomaterial2018-07-11Product approval · Class 4제허 18-491 호
- MFDSGraft/prosthesis, biomaterial2018-05-23Product approval · Class 4제허 18-371 호
- MFDSGraft/prosthesis, biomaterial2018-02-09Product approval · Class 4제허 18-79 호
- MFDSGraft/prosthesis, biomaterial2017-12-20Product approval · Class 4제허 17-966 호
- MFDSDressing, fluid-impermeable film2017-12-18Product approval · Class 2제인 17-4973 호
- MFDSTissue supplement, collagen2017-07-24Product approval · Class 4제허 17-545 호
- MFDSGraft/prosthesis2017-05-15Product approval · Class 4제허 17-314 호
- MFDSGraft/prosthesis, biomaterial2017-04-18Product approval · Class 4제허 17-271 호
- MFDSGraft/prosthesis2017-04-14Product approval · Class 4제허 17-268 호
- MFDSInfusion pump, electrically-poweredRevoked2016-10-24Product approval · Class 2제인 16-4817 호
- MFDSDressing, secondardy treatment, high-absorbent, foam/ sheet/ liquid/powder2016-05-11Product approval · Class 3제허 16-352 호
- MFDSGraft/prosthesis, biomaterial2016-04-22Product approval · Class 4제허 16-310 호
- MFDSGraft/prosthesis, biomaterial2016-03-24Product approval · Class 4제허 16-219 호
- MFDSGraft/prosthesis, biomaterial2015-11-25Product approval · Class 4제허 15-1616 호
- MFDSGraft/prosthesis, biomaterial2015-08-19Product approval · Class 4제허 15-1317 호
- MFDSGraft/prosthesis, biomaterial2015-08-19Product approval · Class 4제허 15-1318 호
- MFDSGraft/prosthesis, biomaterial2015-08-17Product approval · Class 4제허 15-1313 호
- MFDSGraft/prosthesis, biomaterial2015-06-22Product approval · Class 4제허 15-988 호
- MFDSDressing, secondardy treatment, high-absorbent, foam/ sheet/ liquid/powder2015-06-11Product approval · Class 3제허 15-921 호
- MFDSDressing, secondardy treatment, high-absorbent, foam/ sheet/ liquid/powder2015-06-11Product approval · Class 3제허 15-922 호
- MFDSDressing, secondardy treatment, high-absorbent, foam/ sheet/ liquid/powder2015-06-11Product approval · Class 3제허 15-923 호
- MFDSDressing, secondardy treatment, high-absorbent, foam/ sheet/ liquid/powder2015-06-11Product approval · Class 3제허 15-924 호
- MFDSGraft/prosthesis, biomaterial2015-03-31Product approval · Class 4제허 15-452 호
- MFDSDressing, collagen, wound2015-02-13Product approval · Class 3제허 15-207 호
- MFDSGraft/prosthesis, biomaterial2013-11-04Product approval · Class 4제허 13-1868 호
- MFDS drugFlucazole Cap. 50mg2013-07-31Drug · Prescription · Approval201308613
- MFDSBandage, compressionRevoked2013-05-28Product approval · Class 1대구 제신 13-23 호
- MFDSDressing, adhesion barrier2013-05-08Product approval · Class 3제허 13-815 호
- MFDSDressing, adhesion barrier2012-10-17Product approval · Class 3제허 12-1313 호
- MFDS drugRinger Light Sol.2012-09-17Drug · Prescription · Notification201206825
- MFDSGraft/prosthesis, biomaterial2011-12-05Product approval · Class 4제허 11-1322 호
- MFDS탄력밴드Revoked2008-01-23Product approval · Class 1경인 제신 08-20 호
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2022 (Bioequivalence 1)
- Bioequivalence비엔씨다파정10밀리그램(다파글리플로진프로판디올수화물)2022-03-28
2 trial sites
R&D and key agreements
Source: DART corporate disclosureBKP001 · 대사질환 · 초기기술습득단계 · Licensed to Chinese company E Corp for worldwide rights (excluding China, Russia, Mexico, Turkey, Pakistan), signed February 27, 2019, total contract value KRW 2.4 billion, 3% royalty on net sales.
BKP005 · 샘플대기단계 · Licensed to U.S. company N Corp for sales rights (Korea) and manufacturing rights (Asia); total contract value KRW 1.2 billion, 8% royalty on net sales, based on nano-formulation technology.
Antroquinonol(Hocena) · COVID-19 · 미국 FDA 임상2상 완료 · Licensed COVID-19 treatment Antroquinonol (brand name Hocena) from Taiwan's Golden Biotechnology Corporation for Korea, Brazil, Turkey, and Indonesia (contracted January 2021, amended November 2022); total contract value up to USD 15 million upon Phase 3 completion and approval, with a 12% royalty.
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- A Validated Chiral LC-MS/MS Method for the Enantioselective Determination of (S)-(+)- and (R)-(-)-Ibuprofen in Dog Plasma: Its Application to a Pharmacokinetic Study.
Pharmaceutics · 2023-03 · Choi S, Shim WS, Yoon J 외 5
Patents
KIPRIS · applicant-matchedPCT · Published · 2025-11 · Application PCT/KR2025/019357
US · Published · 2024-12 · Application 18966037
TW · Published · 2023-11 · Application 112146580
CN · Published · 2023-05 · Application 202380044541.1
Published · 2023-05 · Application 1020247043113
EP · Published · 2023-05 · Application 23816179.8
PCT · Published · 2023-05 · Application PCT/JP2023/021073
US · Published · 2022-12 · Application 19119142
PCT · Published · 2022-12 · Application PCT/KR2022/020742
Registered · 2022-10 · Application 1020220130968
Show 10 more patents
Registered · 2022-08 · Application 1020220104517
Registered · 2022-08 · Application 1020220104518
Withdrawn · 2021-12 · Application 1020210192605
US · Published · 2021-12 · Application 18267715
PCT · Published · 2021-12 · Application PCT/JP2021/047323
Registered · 2018-09 · Application 1020180114285
Rejected · 2016-04 · Application 1020160052318
Registered · 2015-01 · Application 1020150004244
PCT · Published · 2011-08 · Application PCT/KR2011/006443
Registered · 2010-10 · Application 1020100097884
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive7
- OpenAIOAI-SearchBot114
- GoogleGoogleOther11
- PerplexityPerplexityBot4
- AnthropicClaudeBot2
Measured since Aug 27, 2026 · 4 AI engines · last read Oct 10, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for BNC KOREA, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.
KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.
KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.
L&C BIO manufactures human tissue grafts across 11 tissue types, including the acellular dermal matrix MegaDerm, plus tissue-based medical devices.
Cord blood storage and cell therapy company that has expanded into global CDMO manufacturing and overseas medical network services.
KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.
Wonbiogen Co.,Ltd., established September 2018, listed on KOSDAQ in December 2018, manufactures wound dressings and moist wound dressings.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition